Research
Two new 16-week tuberculosis regimens advance in clinical trial
The Brief
- Two new 16-week tuberculosis treatment regimens have advanced in a clinical trial.
- Tuberculosis causes more than 1 million deaths each year, according to the source.
- Current TB treatment is described as lengthy and burdened by side effects.
Why it matters
Shorter TB regimens could reduce treatment duration and side-effect burden for patients, which matters for global infectious disease control.
Who’s affected
- clinicians and public health officials working on tuberculosis
- researchers in infectious disease and drug development
- #tuberculosis
- #clinical trial
- #infectious disease
- #drug development
- #treatment regimen
Tuberculosis remains one of the world's deadliest infectious diseases, causing more than 1 million deaths each year. The development of new therapeutic regimens remains slow, costly and complex, while treatment remains lengthy and patients face the burden of side effects…